AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic For RYBREVANT® or RYBROFAZ® plus Chemotherapy

 TOKYO and XIAMEN, April 28, 2026 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”) as a companion diagnostic (CDx) for RYBREVANT® or RYBROFAZ® plus chemotherapy in Japan.  Read the full story here:

EGFRins_Ami_PLC_RG-ADx-PREMIA_Fin.pdf

Download PDF • 391KB